Gatta Blandine, Chabre Olivier, Cortet Christine, Martinie Monique, Corcuff Jean-Benoît, Roger Patrick, Tabarin Antoine
Department of Endocrinology, University Hospital of Bordeaux, 33600 Pessac, France.
J Clin Endocrinol Metab. 2007 Nov;92(11):4290-3. doi: 10.1210/jc.2006-2829. Epub 2007 Jul 17.
The diagnostic accuracy of the combined dexamethasone suppression test (DST)-CRH test for the differential diagnosis between Cushing's disease (CD) and pseudo-Cushing syndrome (PCS) has recently been debated.
Our objective was to reevaluate the performance of the DST-CRH test to differentiate CD from PCS and compare it with that of midnight plasma cortisol measurement.
The study took place at three specialized tertiary care university hospitals.
Fourteen patients with PCS and 17 patients with CD matched for 24-h urinary free cortisol were retrospectively studied.
Diagnosis or exclusion of CD was the main outcome measure.
A 55 nmol/liter cortisol concentration after dexamethasone (DST) yielded 94% sensitivity, 86% specificity, and 90% diagnostic accuracy. Using the historical 38 nmol/liter threshold for plasma cortisol 15 min after CRH administration, the DST-CRH test achieved 100% sensitivity, 50% specificity, and 77% diagnostic accuracy. Increasing the threshold to 110 nmol/liter improved the specificity and diagnostic accuracy to 86 and 93.5%, respectively. However, diagnostic accuracy was not significantly different from that of the DST. A midnight plasma cortisol concentration of more than 256 nmol/liter was consistent with the diagnosis of CD with 100% sensitivity, specificity, and diagnostic accuracy.
The diagnostic performance of the DST-CRH test for the differential diagnosis between PCS and mild CD was lower than previously reported. Although the specificity of the test is improved using a revised cortisol threshold, its diagnostic accuracy is not better than that of the standard DST. Our study supports the preferential use of the DST and midnight plasma cortisol measurement as first-line diagnostic tests in equivocal cases.
联合地塞米松抑制试验(DST)-促肾上腺皮质激素释放激素(CRH)试验用于库欣病(CD)和假性库欣综合征(PCS)鉴别诊断的诊断准确性最近受到了争议。
我们的目的是重新评估DST-CRH试验区分CD和PCS的性能,并将其与午夜血浆皮质醇测量的性能进行比较。
该研究在三家专业的三级护理大学医院进行。
对14例PCS患者和17例24小时尿游离皮质醇匹配的CD患者进行回顾性研究。
CD的诊断或排除是主要观察指标。
地塞米松(DST)后皮质醇浓度为55 nmol/升时,敏感性为94%,特异性为86%,诊断准确性为90%。使用CRH给药后15分钟血浆皮质醇的历史阈值38 nmol/升,DST-CRH试验的敏感性为100%,特异性为50%,诊断准确性为77%。将阈值提高到110 nmol/升后,特异性和诊断准确性分别提高到86%和93.5%。然而,诊断准确性与DST的诊断准确性没有显著差异。午夜血浆皮质醇浓度超过256 nmol/升与CD诊断一致,敏感性、特异性和诊断准确性均为100%。
DST-CRH试验用于PCS和轻度CD鉴别诊断的诊断性能低于先前报道。虽然使用修订后的皮质醇阈值可提高试验的特异性,但其诊断准确性并不优于标准DST。我们的研究支持在疑难病例中优先使用DST和午夜血浆皮质醇测量作为一线诊断试验。